Pharmacological interventions for Problematic Usage of the Internet (PUI): A narrative review of current progress and future directions
Pharmacological interventions for Problematic Usage of the Internet (PUI): A narrative review of current progress and future directions
Problematic Usage of the Internet (PUI) represents a spectrum of excessive online behaviors and is linked to reduced quality of life and high rates of psychiatric comorbidity, with growing demand for effective treatments. This paper provides a narrative review of pharmacological studies for PUI conducted to date. Most pharmacological treatment trials have focused on bupropion and escitalopram or involved samples with common comorbidities and used current treatments for the relevant comorbid disorders. Overall, there remains a dearth of high-quality evidence, with the current literature lacking control groups, large sample sizes, validated outcome measures, longer term treatment and follow-up periods. The literature cannot at this stage determine evidence-based pharmacological treatments for PUI.
Solly, Jeremy E
b3341839-0b3c-4660-be99-af4f8178a99f
Grant, Jon E.
15ed8f1b-3f52-4576-b842-1056cf9331b0
Chamberlain, Samuel
8a0e09e6-f51f-4039-9287-88debe8d8b6f
1 August 2022
Solly, Jeremy E
b3341839-0b3c-4660-be99-af4f8178a99f
Grant, Jon E.
15ed8f1b-3f52-4576-b842-1056cf9331b0
Chamberlain, Samuel
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Solly, Jeremy E, Grant, Jon E. and Chamberlain, Samuel
(2022)
Pharmacological interventions for Problematic Usage of the Internet (PUI): A narrative review of current progress and future directions.
Current Opinion in Behavioral Sciences, 46, [101158].
(doi:10.1016/j.cobeha.2022.101158).
Abstract
Problematic Usage of the Internet (PUI) represents a spectrum of excessive online behaviors and is linked to reduced quality of life and high rates of psychiatric comorbidity, with growing demand for effective treatments. This paper provides a narrative review of pharmacological studies for PUI conducted to date. Most pharmacological treatment trials have focused on bupropion and escitalopram or involved samples with common comorbidities and used current treatments for the relevant comorbid disorders. Overall, there remains a dearth of high-quality evidence, with the current literature lacking control groups, large sample sizes, validated outcome measures, longer term treatment and follow-up periods. The literature cannot at this stage determine evidence-based pharmacological treatments for PUI.
Text
PUI pharmacology review v6 for submission
- Accepted Manuscript
Restricted to Repository staff only until 11 June 2023.
Request a copy
More information
Accepted/In Press date: 8 May 2022
e-pub ahead of print date: 11 June 2022
Published date: 1 August 2022
Identifiers
Local EPrints ID: 457502
URI: http://eprints.soton.ac.uk/id/eprint/457502
ISSN: 2352-1546
PURE UUID: 33824b29-7e26-48ec-b5a1-b4cd5b0328f2
Catalogue record
Date deposited: 09 Jun 2022 17:09
Last modified: 09 Dec 2022 03:00
Export record
Altmetrics
Contributors
Author:
Jeremy E Solly
Author:
Jon E. Grant
Author:
Samuel Chamberlain
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics